Top 8 Best-Selling Orphan Drugs Approved and Launched During 2012

In Market Access by Tim PeplowLeave a Comment

best-selling orphan drugs 2012 (epsos .de)

The following 8 drugs are the best-selling drugs with orphan drug designation (according the FDA search here).

1. Kalydeco – Orphan drug designated 12-20-2006 – Treatment of patients with cystic fibrosis – $171.6 million – Vertex Pharmaceuticals – FDA approved Jan 31 2012

2. Kyprolis – Orphan drug designated 01-18-2008 – Treatment of multiple myeloma – $64 million – Onyx Pharmaceuticals – FDA approved July 20 2012

3. Stivarga – Orphan drug designated 01-12-2011 – Treatment gastrointestinal stromal tumors – $41.4 million – Bayer HealthCare and Onyx Pharmaceuticals – FDA approved Aug 27 2012

4. Elelyso – Orphan drug designated 09-03-2009 – Treatment of Gaucher’s disease – $18 million – Protalix BioTherapeutics and Pfizer – FDA approved May 1 2012

5. Bosulif – Orphan drug designated 02-24-2009 – Treatment of chronic myelogenous leukemia – $15 million – Pfizer – FDA approved Sept 4 2012

6. Voraxaze – Orphan drug designated 08-19-2003 – Treatment of patients at risk of methotrexate toxicity – $14 million – BTG International – FDA approved Jan 17 2012

7. Fycompa – Orphan drug designated 12-07-2012 – Treatment of Lennox-Gastaut Syndrome – $12 million -  Eisai – FDA approved Oct 22 2012

8. Signifor – Orphan drug designated 07-24-2009 – Treatment of Cushing’s disease – $3 million – Novartis – FDA approved Dec 14 2012

The data above is from the FDA Orphan Drug Designation and Approval Search and from the Genetic Engineering and Biotechnology News.

What do you think? Are there any surprises on there?

You might be interested in attending the 4th World Orphan Drug Congress Europe, in Geneva on the 14th November 2013.

Leave a Comment

Current ye@r *